ANDA 203711, held by Qilu Pharm Hainan. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 203711 (Ondansetron Hydrochloride), held by Qilu Pharm Hainan, was first approved by FDA on Sep 8, 2014, with 5 approved supplements and 0 published complete response letters.
1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron Injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Ondansetron Injection is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron Injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 8, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Rx |
| Sep 16, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 28, 2022 | Supplement 13Labeling · Standard review | Approved | None posted |
| Sep 1, 2021 | Supplement 2Labeling · Standard review | Approved | None posted |
| Sep 1, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 3, 2015 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 8, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters